68Ga-DOTA-TOC PET/CT检测骨软化症相关肿瘤的诊断效能及对患者管理的影响
该回顾性研究纳入15例有肿瘤性骨软化症临床和生化征象的患者,评估68Ga-DOTA-TOC PET/CT检测致病肿瘤的诊断效能及对患者管理的影响。结果显示灵敏度73%、特异度67%、准确率71%,67%的病例管理受到影响,在既往生长抑素受体SPECT/CT或FDG PET/CT失败后仍有价值。
要点
- 68Ga-DOTA-TOC PET/CT检测肿瘤性骨软化症致病肿瘤的灵敏度73%、特异度67%、准确率71%。
- 68Ga-DOTA-TOC PET/CT影响了67%病例的患者管理。
- 在既往111In-pentetreotide SPECT/CT阴性或假阳性者中5/8(63%)可检出肿瘤。
核心结论
- 68Ga-DOTA-TOC PET/CT是检测肿瘤性骨软化症致病肿瘤的准确影像方法,尤其在生长抑素受体SPECT(/CT)或FDG PET/CT失败后有价值。
研究设计与样本
- 回顾性分析15例有肿瘤性骨软化症临床和生化征象患者的68Ga-DOTA-TOC PET/CT及临床和影像资料,并与术后病理及临床生化随访结果比较。
主要发现
- 68Ga-DOTA-TOC PET/CT在15例中9例(60%)检出可疑肿瘤性骨软化症病灶,其中8例手术切除肿瘤,术后病理证实为肿瘤性骨软化症,症状迅速缓解且生化异常消退。
- 68Ga-DOTA-TOC PET/CT的灵敏度为73%、特异度为67%、准确率为71%。
- 68Ga-DOTA-TOC PET/CT影响了67%病例的患者管理。
- 在既往111In-pentetreotide SPECT/CT阴性或假阳性者中,68Ga-DOTA-TOC PET/CT检出肿瘤性骨软化症5/8例(63%);在既往FDG PET/CT阴性或假阳性者中检出7/11例(64%)。
- 68Ga-DOTA-TOC PET/CT阳性与血清生化标志物水平之间未发现密切关系;仅1例血清FGF23水平不高的患者获得真阳性结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Oncogenic osteomalacia is an endocrine disorder induced by small benign tumours (TIO) producing excessive fibroblast growth factor-23 (FGF23). The only way of curing oncogenic osteomalacia is surgical resection of the culprit TIO, which is extremely difficult to detect using conventional imaging modalities due to its small size and variable location in the body. Since TIO frequently overexpress somatostatin receptors, a clinical utility of SPECT or PET with radiolabelled somatostatin analogues has been reported. Among them, 68Ga-DOTA-TOC has recently been granted a marketing authorization, facilitating its routine application. We report here the results of the first series evaluating the diagnostic performance of 68Ga-DOTA-TOC PET/CT in detecting TIO and its impact on patient management. METHODS: 68Ga-DOTA-TOC PET/CT and clinical and imaging data from 15 patients with clinical and biochemical signs of oncogenic osteomalacia were retrospectively reviewed. The 68Ga-DOTA-TOC PET/CT findings were compared with the results of post-surgical pathology and clinical and biochemical follow-up. RESULTS: 68Ga-DOTA-TOC PET/CT resulted in the detection of one focus suspicious for TIO in nine of 15 patients (60%), and a tumour was surgically removed in eight. Post-operative pathology confirmed a TIO in those eight patients whose symptoms diminished promptly and biochemical anomalies resolved. 68Ga-DOTA-TOC PET/CT sensitivity, specificity and accuracy were 73%, 67% and 71%, respectively. 68Ga-DOTA-TOC PET/CT findings affected patient management in 67% of cases. In particular, 68Ga-DOTA-TOC PET/CT was able to detect the TIO with a negative or a false-positive result of a previous 111In-pentetreotide SPECT/CT in 5/8 patients (63%) or a previous FDG PET/CT in 7/11 patients (64%). No close relationship was found between the positivity of 68Ga-DOTA-TOC PET/CT and the serum level of a biochemical marker. However, a true-positive result of 68Ga-DOTA-TOC PET/CT was obtained in only one patient with a non-elevated serum level of FGF23. CONCLUSION: 68Ga-DOTA-TOC PET/CT is an accurate imaging modality in the detection of TIO; in particular, it is worthwhile after failure of somatostatin receptor SPECT(/CT) or FDG PET/CT.
引用
- Paquet M, Gauthé M, Zhang Yin J, et al. Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours. Eur J Nucl Med Mol Imaging. 2018. PMID: 29532101. doi:10.1007/s00259-018-3971-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。